Endocrine Abstracts

Background: Chronic kidney disease secondary to type 2 diabetes is associated with multifactorial energy dysmetabolism. Irisin has been identified recently as an exercise induced hormone secreted by skeletal muscles. It is hypothesised that patients with CKD may have altered irisin levels.

Aim of the work: We aimed to study irisin hormone in type 2 diabetic patient and to assess its relation with diabetic nephropathy (DN).

Subjects and methods: We recruited 60 type 2 diabetic subjects and 30 healthy controls. Diabetics will be divided into 30 patients without complications and 30 with DN. Serum irisin, fasting blood glucose (FBG), 2 h plasma glucose (2 h PG), HbA1c, serum creatinine, and albumin/creatinine ratio were measured.

Results: Irisin was significantly decreased in type 2 diabetic patients compared to control (34.46±15.28 ng/ml vs 152.600±39.581 ng/ml, P<0.001). Patients with DN had lower irisin than diabetics without complications (20.967±4.476 ng/ml vs 47.967±8.853 ng/ml, P<0.01). There was a significant negative correlation between irisin and systolic blood pressure (r=−0.493), diastolic blood pressure (r=−0.625), serum creatinine (r=−0.729), duration of diabetes (r=−0.942), albumin/creatinine ratio (r=−0.696), BMI (r=−0.396), and HbA1c (r=−0.305) in all diabetic patients.(P<0.05). Multivariant regression analysis showed that duration of diabetes is the only independent determinant for irisin level.

Conclusion: There is a decrease in serum irisin level in patients with type 2 diabetes and a further significant decrease in patients with DN.